NASDAQ:VBLT - Vascular Biogenics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vascular Biogenics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.49 +0.16 (+12.03 %) (As of 02/28/2020 04:00 PM ET) Add Compare Today's Range$1.25Now: $1.49▼$1.5250-Day Range$1.33MA: $1.43▼$1.5752-Week Range$0.93Now: $1.49▼$1.90Volume108,322 shsAverage Volume110,588 shsMarket Capitalization$53.46 millionP/E RatioN/ADividend YieldN/ABeta0.63 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VBLT Previous SymbolNASDAQ:VBLX CUSIPN/A CIK1603207 Webhttp://www.vblrx.com/ Phone972-8993-5000Debt Debt-to-Equity Ratio0.06 Current Ratio5.49 Quick Ratio5.49Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$580,000.00 Price / Sales92.18 Cash FlowN/A Price / Cash FlowN/A Book Value$1.48 per share Price / Book1.01Profitability EPS (Most Recent Fiscal Year)($0.62) Net Income$-20,460,000.00 Net Margins-3,050.43% Return on Equity-37.19% Return on Assets-30.44%Miscellaneous Employees39 Outstanding Shares35,881,000Market Cap$53.46 million Next Earnings Date3/26/2020 (Estimated) OptionableOptionable Receive VBLT News and Ratings via Email Sign-up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VBLT Rates by TradingView Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions What is Vascular Biogenics' stock symbol? Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT." How were Vascular Biogenics' earnings last quarter? Vascular Biogenics Ltd (NASDAQ:VBLT) posted its quarterly earnings data on Thursday, November, 14th. The biopharmaceutical company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). The biopharmaceutical company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.24 million. Vascular Biogenics had a negative return on equity of 37.19% and a negative net margin of 3,050.43%. View Vascular Biogenics' Earnings History. When is Vascular Biogenics' next earnings date? Vascular Biogenics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Vascular Biogenics. What price target have analysts set for VBLT? 5 brokerages have issued 1-year price objectives for Vascular Biogenics' shares. Their forecasts range from $2.00 to $3.25. On average, they expect Vascular Biogenics' share price to reach $2.75 in the next twelve months. This suggests a possible upside of 84.6% from the stock's current price. View Analyst Price Targets for Vascular Biogenics. What is the consensus analysts' recommendation for Vascular Biogenics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vascular Biogenics. What are Wall Street analysts saying about Vascular Biogenics stock? Here are some recent quotes from research analysts about Vascular Biogenics stock: 1. According to Zacks Investment Research, "Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. " (1/28/2020) 2. Chardan Capital analysts commented, "We understand the colon cancer trial will be a single- arm open label design, providing the possibility of an early look at efficacy signals, with data anticipated in 2020. We expect more details on these programs as the GBM and colon cancer trials begin." (5/16/2019) Has Vascular Biogenics been receiving favorable news coverage? Press coverage about VBLT stock has been trending somewhat negative this week, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vascular Biogenics earned a daily sentiment score of -1.9 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Vascular Biogenics. Are investors shorting Vascular Biogenics? Vascular Biogenics saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 107,200 shares, an increase of 104.2% from the January 30th total of 52,500 shares. Based on an average trading volume of 94,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.4% of the company's stock are sold short. View Vascular Biogenics' Current Options Chain. Who are some of Vascular Biogenics' key competitors? Some companies that are related to Vascular Biogenics include Athersys (ATHX), Chiasma (CHMA), Theratechnologies (THTX), TAIWAN LIPOSOME/S (TLC), Affimed (AFMD), Nature's Sunshine Products (NATR), Aptorum Group (APM), Five Prime Therapeutics (FPRX), Spero Therapeutics (SPRO), Arbutus Biopharma (ABUS), Abeona Therapeutics (ABEO), Evelo Biosciences (EVLO), Scpharmaceuticals (SCPH), Fortress Biotech (FBIO) and Kezar Life Sciences (KZR). What other stocks do shareholders of Vascular Biogenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Verastem (VSTM), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), vTv Therapeutics (VTVT), AEterna Zentaris (AEZS), Onconova Therapeutics (ONTX), Opko Health (OPK) and Corbus Pharmaceuticals (CRBP). Who are Vascular Biogenics' key executives? Vascular Biogenics' management team includes the folowing people: Prof. Dror Harats, CEO & Director (Age 62)Mr. Amos Ron, CFO & Company Sec. (Age 64)Dr. Erez Feige, VP of Bus. Operations (Age 45)Dr. Eyal Breitbart, VP of Research & Operations (Age 52)Dr. Naamit Sher, VP of Drug Devel. & Regulatory Affairs (Age 65) Who are Vascular Biogenics' major shareholders? Vascular Biogenics' stock is owned by many different of retail and institutional investors. Top institutional investors include PVG Asset Management Corp (0.11%) and Renaissance Technologies LLC (0.10%). Which institutional investors are buying Vascular Biogenics stock? VBLT stock was acquired by a variety of institutional investors in the last quarter, including PVG Asset Management Corp and Renaissance Technologies LLC. How do I buy shares of Vascular Biogenics? Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Vascular Biogenics' stock price today? One share of VBLT stock can currently be purchased for approximately $1.49. How big of a company is Vascular Biogenics? Vascular Biogenics has a market capitalization of $53.46 million and generates $580,000.00 in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Vascular Biogenics employs 39 workers across the globe.View Additional Information About Vascular Biogenics. What is Vascular Biogenics' official website? The official website for Vascular Biogenics is http://www.vblrx.com/. How can I contact Vascular Biogenics? Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected] MarketBeat Community Rating for Vascular Biogenics (NASDAQ VBLT)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 253 (Vote Outperform)Underperform Votes: 284 (Vote Underperform)Total Votes: 537MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe VBLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: What does an equal weight rating mean?
